GlioCure
Created in 2016
Up & running (A)
Existing signals show a regular activitySocial networks
151 2,250 2,005Activities
Technologies
Entity types
Location
Institut de Biologie en Santé, Rue des Capucins, 49100 Angers, France
Angers
France
Employees
Scale: 2-10
Estimated: 5
SIREN
822444840Engaged catalyst
12
0 0Added in Motherbase
6 years, 7 months ago
Value proposition
A preclinical-stage drug-development company specialized in neuro-oncology
GlioCure, a spin-off company of Angers and McGill Montreal universities, aims to treat glioblastoma that causes 200,000 deaths worldwide each year.
To overcome this challenge, GlioCure is hyper-specialized and develops glioblastoma-specific drugs.
GlioCure is currently focusing on the development of GC01, an anti-glioblastoma peptide discovered by Joël Eyer, Director of Research from INSERM, and covered by two patent families for which GlioCure owns worldwide exclusive rights.
GlioCure's team has the experience and the know-how to ensure the successful completion of GC01’s development plan:
Louis-Marie is a biotech entrepreneur with 15 years of experience in the field of innovative therapies and rare diseases;
Claire, specialist of the neuronal cytoskeleton, has sound knowledge of preclinical experimental techniques;
Its Scientific & Medical Advisory Board is composed of leading international experts in research and treatment of glioblastoma.
Glioblastoma, Glioma, Neurooncology, Innovative therapies, Nanomedicines, Rare diseases, Neurosurgery, Brain tumors, Orphan drugs, and PeptideOriginal language
A preclinical-stage drug-development company specialized in neuro-oncology
GlioCure, a spin-off company of Angers and McGill Montreal universities, aims to treat glioblastoma that causes 200,000 deaths worldwide each year.
To overcome this challenge, GlioCure is hyper-specialized and develops glioblastoma-specific drugs.
GlioCure is currently focusing on the development of GC01, an anti-glioblastoma peptide discovered by Joël Eyer, Director of Research from INSERM, and covered by two patent families for which GlioCure owns worldwide exclusive rights.
GlioCure's team has the experience and the know-how to ensure the successful completion of GC01’s development plan:
Louis-Marie is a biotech entrepreneur with 15 years of experience in the field of innovative therapies and rare diseases;
Claire, specialist of the neuronal cytoskeleton, has sound knowledge of preclinical experimental techniques;
Its Scientific & Medical Advisory Board is composed of leading international experts in research and treatment of glioblastoma.
Gliocure : Gliocure
https://www.gliocure.com/
| Catalyst | Type | Tweets | Articles | |
|---|---|---|---|---|
 France Biotech Startup accelerator & VC, Biotechnology, Biotechnology Research | France Biotech Startup accelerator & VC, Biotechnology, Biotechnology Research | Not capitalistic Not partnership Event 16 Jan 2017 | | |
 La French Tech Angers French Tech, IT Services and IT Consulting | La French Tech Angers French Tech, IT Services and IT Consulting | Not capitalistic Not partnership Event 22 Nov 2021 26 Feb 2025 | | |